LABA stands for long-acting beta-agonist, a type of inhaled medication that opens the airways for 12 hours or longer. LABAs are one of the most commonly prescribed treatments for asthma and chronic obstructive pulmonary disease (COPD), typically delivered through an inhaler or nebulizer. Unlike rescue inhalers that wear off in a few hours, LABAs provide sustained relief and are taken on a regular schedule, usually once or twice daily.
How LABAs Work
The airways are wrapped in a layer of smooth muscle. In conditions like asthma and COPD, that muscle tightens more than it should, narrowing the passage and making it harder to breathe. LABAs attach to specific receptors on these muscle cells and trigger a chemical signal that tells the muscle to relax. The result is wider airways and easier airflow.
What makes LABAs “long-acting” is the way their molecules interact with these receptors. Short-acting beta-agonists (SABAs) like albuterol bind to the same receptors but wash away quickly, providing relief for only 4 to 6 hours. LABAs hold on longer, keeping the airways open for at least 12 hours. Some newer formulations, sometimes called ultra-LABAs, last a full 24 hours and only need to be inhaled once a day.
LABAs vs. Rescue Inhalers
The distinction between LABAs and SABAs is one of the most important things to understand about asthma and COPD treatment. A SABA like albuterol is a rescue medication. You use it when symptoms flare up and you need fast relief, typically within minutes. A LABA is a maintenance medication. You use it every day on a set schedule to keep symptoms from developing in the first place.
In clinical comparisons, LABAs provide more consistent symptom control than taking a SABA on a regular schedule. They also improve lung function measurements more effectively over time. However, LABAs are not designed for sudden breathing emergencies. They take longer to kick in and are meant to work steadily in the background.
Why LABAs Are Paired With Steroids
If you look at the most well-known LABA inhalers, nearly all of them combine the LABA with an inhaled corticosteroid (ICS) in a single device. Advair, Symbicort, Breo Ellipta, and Dulera all work this way. There’s a specific medical reason for this pairing.
In asthma, the underlying problem is chronic inflammation in the airways. LABAs relax the muscles around the airways but do nothing to treat that inflammation. Inhaled corticosteroids reduce the inflammation but don’t directly open the airways. Together, they tackle both problems at once. Studies show the combination improves lung function and overall health status more than either medication alone, and there’s evidence the two components enhance each other’s effects at the cellular level.
Combining them in a single inhaler also has a practical benefit: it makes it much harder to accidentally use the LABA without the steroid. This matters because of a critical safety concern covered below.
The Safety Rule for Asthma
Using a LABA by itself to treat asthma, without an inhaled corticosteroid, is associated with an increased risk of asthma-related death. The FDA still requires a boxed warning on all single-ingredient LABA products stating this risk. This is why asthma guidelines are clear: LABAs should only be added when asthma remains poorly controlled despite regular use of an inhaled corticosteroid. They are not a first-line treatment for asthma and should never be the only controller medication you use.
The good news is that large safety trials found no significant increase in serious asthma outcomes when LABAs are used in combination with an inhaled corticosteroid. Based on those results, the FDA removed the boxed warning from combination ICS/LABA inhalers. So the risk is specifically tied to using a LABA alone for asthma, not to LABAs in general.
This restriction applies to asthma specifically. In COPD, LABAs can be prescribed on their own or in combination with other medications, because the underlying disease and risk profile are different.
Common LABA Medications
Several LABA molecules are available, and they appear in both standalone and combination inhalers:
- Salmeterol is found in Serevent Diskus (standalone) and in Advair and AirDuo Respiclick (combined with a steroid). It lasts about 12 hours and is taken twice daily.
- Formoterol appears in Perforomist (standalone nebulizer solution) and in Symbicort and Dulera (combined with a steroid). It also lasts around 12 hours.
- Vilanterol is a once-daily LABA found in Breo Ellipta (with a steroid) and Trelegy Ellipta (a triple combination with a steroid and a muscarinic antagonist). It provides 24 hours of bronchodilation.
- Olodaterol is another once-daily option, found in Striverdi Respimat (standalone) and Stiolto Respimat (combined with a muscarinic antagonist), used primarily for COPD.
Triple-therapy inhalers like Trelegy Ellipta and Breztri Aerosphere combine a LABA with an inhaled corticosteroid and a long-acting muscarinic antagonist (LAMA) in a single device. The LAMA works by blocking a different set of receptors that cause airway constriction, giving an additional layer of bronchodilation. Research shows that when the body’s response to a LABA starts to weaken over time, the LAMA component can help maintain airway relaxation through its separate pathway.
How LABAs Are Used in COPD
Inhaled therapy is the cornerstone of COPD treatment, and LABAs play a central role. Unlike in asthma, a LABA can be prescribed alone for COPD as a first-step treatment. For people with more frequent flare-ups, guidelines recommend stepping up to a LABA/LAMA combination or a LABA/ICS combination, and eventually triple therapy if needed. The choice depends on the frequency and severity of exacerbations, as well as blood markers that help predict which patients will benefit most from adding a steroid.
Side Effects
Because LABAs stimulate receptors that exist throughout the body (not just in the lungs), some of the medication’s effects can show up beyond the airways. The most common side effects are tremors, particularly in the hands, and a feeling of nervousness or jitteriness. Some people notice a faster heart rate or palpitations, especially early in treatment.
LABAs can also lower potassium levels in the blood, a condition called hypokalemia. This is more of a concern for older adults, people with heart conditions, or those taking other medications that also affect potassium. Muscle cramps and headaches are reported as well. Rarely, a LABA can cause paradoxical bronchospasm, where the airways tighten instead of relaxing right after inhalation. If breathing suddenly gets worse after using the inhaler, that’s a sign to stop and seek medical attention.
For most people, side effects are mild and tend to settle down as the body adjusts. The inhaled delivery route means far less medication enters the bloodstream compared to taking a pill, which keeps systemic effects relatively low.